hotspot -WSS

hotspot

author：Wikipedia 2025-09-27 13:10:08 - browse：44

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Information blocking fines are now fair game in health care

entertainment

hotspot

WSS

Medicare to pay more for cardiac rehab in hospital outpatient clinics

'A game

What we owe ALS patients — and why one company fell short

How the messy conversation about Dolly changed bioethics

Fed up with FDA, ALS advocates consider a take

The unintended consequences of overturning Roe v. Wade

entertainment

hotspot

Wikipedia

Hollywood unions extend contract negotiations for actors

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Trump demands the U.S. pay no more for drugs than other countries … again

Experts study whether long Covid risk adds up with each reinfection

Wildfire smoke exposes gaps in outdoor worker protections

Midwives could help bridge maternal health disparities in the U.S.

Medical leaders decry Supreme Court decision on affirmative action

Nobel honors Karikó and Weissman's enduring partnership

Bright Health sells Medicare Advantage business to Molina

Chamber of Commerce, DOJ clash in court over drug prices

explore

Akili changes sales model for its ADHD video game treatment

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Medicare innovation center doesn’t save money, experts say

What happened to the House vote on health price transparency?

Patients, doctors press FTC to beef up hospital merger scrutiny

David Liu startup to focus on CRISPR delivery

entertainment

hotspot

hotspot

hotspot